Treating the Infection to Treat the Lymphoma
A single patient with a genuine cancer diagnosis whose first treatment is an antibiotic, not an oncologic regimen. The disagreement isn't about that first step — it's about how long to let an indolent disease's own slow biology play out before treating a delay as a failure.
P.N., a 55-year-old accountant, went in for an EGD after months of vague dyspepsia her primary care physician couldn't otherwise explain, expecting to hear "gastritis" or perhaps an ulcer. Biopsy instead showed low-grade gastric MALT lymphoma — a genuine cancer diagnosis that, unlike almost every other lymphoma a patient might hear about, is not going to be treated first with chemotherapy or radiation. Staging with EUS and CT confirmed disease confined to the stomach wall without nodal or distant involvement, and biopsy confirmed active H. pylori infection.
Gastric MALT lymphoma is one of the few malignancies with a genuinely curative treatment that's an antibiotic regimen rather than an oncologic one, because the disease is driven by chronic antigenic stimulation from H. pylori infection itself — eradicate the antigen, and a substantial majority of early-stage, localized, H. pylori-positive cases achieve durable histologic remission without any chemotherapy, radiation, or surgery at all. This isn't a plausible-sounding mechanism dressed up as treatment; it's a well-established, guideline-endorsed first-line approach specifically because the causal chain from infection to lymphoproliferation has been directly demonstrated.
What actually needs deciding today isn't whether to try eradication first — nobody on the team disputes that — it's what the follow-up plan looks like if it doesn't work: how long to wait before declaring eradication therapy a failure, and what threshold of persistent disease should trigger escalation to radiotherapy rather than a second eradication attempt or continued watchful waiting. Her own reaction to the diagnosis — relief that treatment doesn't start with chemotherapy, layered under real anxiety at hearing the word lymphoma at all — is part of what the team is actually managing alongside the biology, since the follow-up interval decided today is also, functionally, a decision about how long she carries an unresolved cancer diagnosis before either reassurance or escalation.
Deciding how long is long enough to wait
Eradication first isn't in question for either of us — the data for localized, H. pylori-positive MALT lymphoma are strong enough that I don't think anyone on this team would start with radiotherapy. The real decision is how we handle it if remission isn't obvious on the first re-staging.
MALT lymphoma's own natural history matters here: histologic regression can lag well behind H. pylori clearance, sometimes by a year or more, in patients who go on to achieve complete remission without any further treatment. I'd want to allow up to 12 to 18 months of watchful waiting with serial endoscopic surveillance before calling eradication a failure.
I don't dispute the biology — regression genuinely can lag. What weighs on me is what 18 months of "wait and see" actually costs a patient who was told three months ago she has lymphoma.
Radiotherapy for localized gastric MALT lymphoma has excellent efficacy and is well-tolerated — this isn't a treatment with a steep cost we're trying to spare her from. I'd re-stage at three months and move toward radiotherapy promptly if remission isn't clearly underway, rather than ask her to sit with an unresolved cancer diagnosis for over a year on the chance her biology happens to be on the slow end.
That's a real cost I don't want to minimize — the psychological weight of "still cancer, still waiting" is genuine, and I take the point that radiotherapy here isn't a harsh fallback the way it might be for other disease.
I'd propose a middle path: re-stage at three months as you'd want, but if that scope shows any objective improvement — even short of full histologic remission — continue surveillance rather than moving straight to radiotherapy. Only clear non-response or progression at three months triggers escalation now.
H. pylori eradication started as sole first-line therapy, with re-staging endoscopy planned at three months rather than the eighteen-month window originally proposed; any objective improvement at that point, even short of complete remission, continues surveillance rather than triggering radiotherapy.
Genuinely reconciled, not just compromised on paper — the Gastroenterologist's biology and the Radiation Oncologist's concern about open-ended uncertainty both shaped the final threshold, which neither voice fully owned going in.